Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria.

Looareesuwan S, Sjostrom L, Krudsood S, Wilairatana P, Porter RS, Hills F, Warrell DA.

Am J Trop Med Hyg. 1999 Jul;61(1):26-33.

2.

Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria.

Wenisch C, Looareesuwan S, Wilairatana P, Parschalk B, Vannapann S, Wanaratana V, Wernsdorfer W, Graninger W.

Am J Trop Med Hyg. 1998 Mar;58(3):343-7.

3.

Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha.

Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE, Warrell DA.

N Engl J Med. 1996 Aug 1;335(5):311-5.

4.

Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand.

Looareesuwan S, Wilairatana P, Vannaphan S, Wanaratana V, Wenisch C, Aikawa M, Brittenham G, Graninger W, Wernsdorfer WH.

Am J Trop Med Hyg. 1998 Mar;58(3):348-53.

6.

Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.

Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR.

Crit Care Med. 2006 Sep;34(9):2271-81.

PMID:
16810105
7.

Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria.

Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M.

Am J Med. 1989 Aug;87(2):139-43.

PMID:
2667356
8.

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J.

Crit Care Med. 1996 May;24(5):733-42. Erratum in: Crit Care Med 1996 Sep;24(9):1608.

PMID:
8706447
9.

The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever.

Coxon RE, Fekade D, Knox K, Hussein K, Melka A, Daniel A, Griffin GG, Warrell DA.

QJM. 1997 Mar;90(3):213-21.

10.

An open, randomized trial of three-day treatment with artesunate combined with a standard dose of mefloquine divided over either two or three days, for acute, uncomplicated falciparum malaria.

Silachamroon U, Krudsood S, Thanachartwet W, Tangpukdee N, Leowattana W, Chalermrut K, Srivilairit S, Wilaiaratana P, Thimasarn K, Looareesuwan S.

Southeast Asian J Trop Med Public Health. 2005 May;36(3):591-6.

PMID:
16124422
11.
13.

Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria.

Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A, Diatta B, Seignot P, Roussilhon C.

Infect Immun. 1997 Aug;65(8):3271-6.

14.

Plasma levels of the interleukin-6 cytokine family in persons with severe Plasmodium falciparum malaria.

Wenisch C, Linnau KF, Looaresuwan S, Rumpold H.

J Infect Dis. 1999 Mar;179(3):747-50.

15.

Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria.

Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, Kirby PL, Woessner M, Neate C, Nyirenda M, Blencowe H, Dube-Mbeye Q, Kanyok T, Ward S, Molyneux M, Dunyo S, Winstanley PA.

PLoS One. 2008 Mar 5;3(3):e1779. doi: 10.1371/journal.pone.0001779.

16.

The effects of quinine and artesunate treatment on plasma tumor necrosis factor levels in malaria-infected patients.

Ittarat W, Udomsangpetch R, Chotivanich KT, Looareesuwan S.

Southeast Asian J Trop Med Public Health. 1999 Mar;30(1):7-10.

PMID:
10695778
17.

Distinct patterns of cytokine regulation in discrete clinical forms of Plasmodium falciparum malaria.

Akanmori BD, Kurtzhals JA, Goka BQ, Adabayeri V, Ofori MF, Nkrumah FK, Behr C, Hviid L.

Eur Cytokine Netw. 2000 Mar;11(1):113-8.

PMID:
10705308
18.

Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients.

George JF, Kirklin JK, Naftel DC, Bourge RC, White-Williams C, McGiffin DC, Savunen T, Everson MP.

J Heart Lung Transplant. 1997 Oct;16(10):1046-53.

PMID:
9361247
19.

Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or clinical outcome: a prospective, randomized, placebo-controlled study.

Hemmer CJ, Hort G, Chiwakata CB, Seitz R, Egbring R, Gaus W, Hogel J, Hassemer M, Nawroth PP, Kern P, Dietrich M.

Am J Trop Med Hyg. 1997 Apr;56(4):397-403.

PMID:
9158047
20.

Severe malaria in Cameroonian children: correlation between plasma levels of three soluble inducible adhesion molecules and TNF-alpha.

Tchinda VH, Tadem AD, Tako EA, Tene G, Fogako J, Nyonglema P, Sama G, Zhou A, Leke RG.

Acta Trop. 2007 Apr;102(1):20-8. Epub 2007 Feb 27.

PMID:
17397790
Items per page

Supplemental Content

Write to the Help Desk